Phase II Study of BNC210 in PTSD

Post-Traumatic Stress Disorder Clinical Trial

— RESTORE  

Official title:

A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02933606
• Other study ID #: BNC210.007
• Status: Completed
• Phase: Phase 2
• Start date: June 30, 2016
• Est. completion date: July 25, 2018

Study information

• Verified date: February 2023
• Source: Bionomics Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).

The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 193
• Est. completion date: July 25, 2018
• Est. primary completion date: July 5, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Key Inclusion Criteria:

• Signed and dated informed consent.

• Male or female between 18 and 70 years of age, inclusive.

• Diagnosed with current PTSD as defined by the CAPS-5 for DSM-5.

• Currently not using any psychiatric medications except for:

• No more than one selective serotonin reuptake inhibitor (SSRI) (fluvoxamine is excluded) or serotonin noradrenaline reuptake inhibitor (SNRI) within the licensed prescribing dose range. Subjects must have been on a stable dose for at least 3 months prior and through Screening, with the intent to remain on the same dose through to Week 16.

• As needed (PRN) use of benzodiazepines (BZD) at a frequency not exceeding 2 days per week in the 3 months prior to Screening. The total dose must not exceed 30 mg/day in diazepam equivalents.

• Subjects not currently receiving psychotherapy except long term supportive counseling or subjects that have received intensive regular psychotherapy for a minimum of three months prior to Screening.

• Females of childbearing potential must have a negative serum pregnancy. Females not of childbearing potential must be postmenopausal. Sterilized male patients must be at least 1 year post-vasectomy to be considered of non-child bearing potential. Females and males of childbearing potential must agree to use two effective methods of contraception.

Key Exclusion Criteria

• Current and ongoing exposure to the trauma that caused the PTSD.

• Failed more than three trials of antidepressant medication(s) prescribed for the treatment of PTSD. Each trial must have lasted at least 6 weeks to be considered a failed attempt. A trial that was terminated due to intolerability or side effects does not constitute a failed attempt.

• The use of psychiatric medications within 2 weeks of Screening except for SSRIs, SNRIs or limited PRN BZD use as per inclusion criterion 4. Restricted psychiatric medications include (but are not limited to) antidepressants not allowed by inclusion criterion 4, antianxiety drugs (except limited BZD use per inclusion criterion 4), mood stabilizers, stimulants, antipsychotics, hypnotics and acetylcholinesterase inhibitors.

• History of significant traumatic brain injury.

• Depression as measured by Montgomery-Äsberg depression scale (MADRS) rating > 23.

• Bipolar and psychotic disorders as identified at Screening using the MINI International Neuropsychiatry Interview (V7.0) (M.I.N.I).

• A score = 7 on the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) at Screening.

• History of seizure disorders, uncontrolled sleep apnoea or severe neurologic disease.

• Increased risk of suicide, defined as:

• Any previous suicide attempt disclosed by the participant at Screening using the Columbia Suicide Severity Rating Scale (C-SSRS).

• Any suicidal ideation with intent (yes to item 4 and / or 5) or suicidal behavior in the past year, as captured at Screening using the C-SSRS.

• A score > 4 on item 10 of the MADRS at Screening.

• The use of alprazolam or flunitrazepam within 3 months of Screening.

• Any clinically significant abnormalities in laboratory test results, vitals signs, or ECG at Screening.

• Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) at Screening.

• Any moderate to severe substance use disorder (any type) in the 12 months prior to Screening as identified by the DSM-5 using the M.I.N.I (V7.0).

• Current Australian serving Defense personnel or any member of the US military currently serving on active duty.

• Participants involved with ongoing insurance or workplace claims that in the opinion of the Investigator are likely to have an impact on the mental health, presentation or capacity of the patient to engage in the study.

Related Conditions & MeSH terms

• Post-Traumatic Stress Disorder
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Intervention

Drug:
• BNC210

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bionomics Limited

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score	Investigator-rated PTSD symptom severity.; The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.	12 weeks.
Secondary	Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).	Self-reported PTSD symptom severity.; The range for the Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5) Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.	12 weeks.
Secondary	Montgomery- Åsberg Depression Rating Scale (MADRS).	Depression severity.; The range for the Montgomery- Åsberg Depression Rating Scale (MADRS) is 0-60, with a higher score meaning a higher severity of disease.	12 weeks.
Secondary	Hamilton Anxiety Rating Scale (HAM-A).	Anxiety severity.; The range for the Hamilton Anxiety Rating Scale (HAM-A) is 0-56, with a higher score meaning a higher severity of disease.	12 weeks
Secondary	Clinical Global Impressions - Severity Scale (CGI-S).	Clinician's assessment of global symptom severity using the Clinical Global Impressions - Severity Scale (CGI-S).	12 weeks
Secondary	Clinical Global Impressions - Improvement Scale (CGI-I).	Clinician's assessment of global symptom improvement using the Clinical Global Impressions - Improvement Scale (CGI-I).	12 weeks
Secondary	Patient Global Impressions - Severity Scale (PGI-S).	Self-reported global symptom severity using the Patient Global Impressions - Severity Scale (CGI-S).	12 weeks.
Secondary	Patient Global Impression - Improvement Scale (PGI-I).	Self-reported global symptom improvement using the Patient Global Impression - Improvement Scale (PGI-I).	12 weeks.
Secondary	Assessment of Quality of Life (AQoL-8D).	Quality of Life.; The range for the Assessment of Quality of Life (AQoL-8D) score is 35-176, with a higher score meaning a lower quality of life.	12 weeks.
Secondary	Social Functioning: Sheehan Disability Scale (SDS).	Social functioning.; The range for the Total Score on the Sheehan Disability Scale (SDS) is 0-30, with a higher score meaning a higher degree of impairment.	12 weeks.
Secondary	Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).	Sleep quality and duration.; The range for the Pittsburgh Sleep Quality Index (PSQI) score is 0-21, with a higher score meaning a worse level of sleep quality	12 weeks.
Secondary	CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment	The CANTAB global composite score is based on the Z scores for CANTAB outcome measures (PAL first attempt memory score (PALFAMS), PAL total errors adjusted (PALTEA), SWM between errors (SWMBE), SWM strategy (SWMS), RVP A' prime (RVPA), RVP median latency (RVPMDL). Specifically, the global composite score of cognitive function is as follows: CANTAB global composite score of cognitive function = (ZPALFAMS + ZPALTEA + ZSWMBE + ZSWMS + ZRVPA + ZRVPMDL) /8 (higher is better); A Z-score of 0 represents the population mean. A Z-score above 0 indicates cognition higher than the population mean and Z-score below 0 indicates cognition lower than the population mean	12 Weeks